Antibiotics Pharmaceutical Intermediate Raw Powder CAS 61622-34-2 Bulk Cefotiam with Best Quality

• Customization: Available
• Powder: Yes
• Customized: Customized
• Suitable for: Adult
• State: Powder
• Purity: >99%
• CAS No.: 61622-34-2
• Mf: C18h23n9o4s3
• Appearance: White Powder
• Grade: Medicine Grade and Food Grade
• MW: 525.63
• Size: 100% Pass 80 Mesh
• Einecs: -
• Transport Package: Paper Bag or Drum
• Specification: 1kg/bag; 25kg/drum
• Trademark: Greenway Biotech
• Origin: China
• HS Code: 2942000000
• Production Capacity: 1000kg/Year

Product Description

Antibiotics Pharmaceutical Intermediate Raw Powder Cas 61622-34-2 Bulk
Cefotiam with Best Quality

Product Name	Cefotiam
Brand Name	Greenway Biotech
Purity	99%
CAS No.	61622-34-2
Appearance	White Powder
Test Method	HPLC

     Mainly used for sensitive to this product are Staphylococcus, Streptococcus (except for
bacteria), pneumococcus, influenza bacilli, Escherichia coli, Klebsiella, intestinal bacteria,
Citrobacter, Proteus mirabilis , Proteus vulgaris, Proteus vulgaris, Proteus proteus, etc. The
following infections: sepsis, postoperative infection, burn infection, subcutaneous abscess,
bloated, boil, boil, osteomyelitis, septic arthritis, tonsillitis , Bronchitis, bronchodilation with
infection, pneumonia, pulmonary suppuration, empyema, cholangitis, cholecystitis, peritonitis,
pyelonephritis, cystitis, urethritis, prostatitis, meningitis, endometritis, pelvic Inflammation,
parapneumonitis, annex inflammation, vestibular mastitis, otitis media, sinusitis. 


Function:

Cefotiam inhibits final cross-linking stage of peptidoglycan production, thus inhibiting
bacterial cell wall synthesis. It has similar or less activity against Gram-positive staphylococci
and streptococci, but is resistant to some beta-lactamases produced by Gram-negative
bacteria. It is more active against many of the Enterobacteriaceae including Enterobacter,
E. coli, Klebsiella, Salmonella and indole-positive Proteus species.

For adults, the dose is up to 6 grams daily by intravenous or intramuscular route in divided
doses according to severity of infection. In patients with renal impairment a dose reduction
may be needed.